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Abstract 
Objective 
To describe the age pattern and temporal evolution of symptoms and signs of intracranial tumours 
in children and young adults before diagnosis. 
Design and setting 
A record linkage study using population-based data from the National Cancer Registry, linked to 
Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). 
Patient cohort 
Patients aged 0–24 years when diagnosed with a primary intracranial tumour between 1989 and 
2006 in England. 
Methods 
Linked records of relevant symptoms and signs in primary care and hospitals were extracted from 
CPRD (1989–2006, 181 patients) and HES (1997–2006, 3,959 patients). Temporal and age-
specific changes in presentation rates before diagnosis of an intracranial tumour, for each of eight 
symptom groups, were estimated in generalised additive models. 
Results 
All symptoms presented with increasing frequency until eventual diagnosis. The frequency of 
presentation of raised intracranial pressure to hospitals rose rapidly to 36.4 per 100 person-months 
(95% CI: 34.6–38.4) in the final month before diagnosis in the entire cohort. Clinical features in 
primary care were less specific: the main features were visual disturbance (rate: 0.49 per 100 
person-months; 95% CI: 0.33–0.72) in 0–4 year-olds, headache in 5–11 year-olds (0.64; 0.47–
0.88), 12–18 year-olds (1.59; 1.21–2.08) and 19–24 year-olds (2.44; 1.71–3.49). The predominant 
features at hospital admission were those of raised intracranial pressure: between 1.17 per 100 
person-months (95% CI: 1.08–1.26) in 0–4 year-olds and 0.77 (0.67–0.88) in 19–24 year-olds. 
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Conclusions 
Non-localising symptoms and signs were more than twice as common as focal neurological signs. 
An intracranial tumour should be considered in patients with relevant symptoms that do not resolve 
or that progress rapidly. 
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Introduction 
Over 500 patients aged 0–24 years are diagnosed with an intracranial tumour in England 
annually.[1] Intracranial tumours took longer to diagnose than many other childhood cancers.[2-7] 
There has been considerable interest in reducing the time interval between symptom onset and 
diagnosis to improve survival and quality of life, and has led to the production of guidelines [8] and 
introduction of a campaign (“HeadSmart – be brain tumour aware”, www.headsmart.org.uk) to 
reduce the symptomatic interval of intracranial tumours before their diagnosis in children and 
teenagers. 
Recent studies on early diagnosis have largely focused on the predictive power of symptoms and 
signs for all cancers.[9-15] Intracranial tumours are distinctive in their diversity of clinical features, 
and thus warrant an in-depth investigation into presentation patterns in relation to their natural 
history and the diagnostic process. Recent advances in record linkage methods [16-18] have 
created such an opportunity for studying the history of presentation in primary care and National 
Health Service (NHS) hospitals. We described the sequence of symptoms and signs in both 
primary and secondary care leading up to the eventual diagnosis of an intracranial tumour, using 
linked medical records from Clinical Practice Research Datalink (CPRD) and Hospital Episode 
Statistics (HES) in a population-based cohort with histologically verified tumours. 
Data source 
The Office for National Statistics (ONS) has been collating information on tumour pathology and 
patient vital status in England to maintain the National Cancer Registry since 1971. Data quality is 
audited regularly on ascertainment, timeliness, completeness, accuracy and validity.[19 20] 
Ascertainment of central nervous system tumours is over 98%.[21] Fewer than 1% of registrations 
are of poor quality.[20] Agreement between pathology reports and registry data within broad 
diagnostic group was 93%, with the date of diagnosis within six weeks of each other in 94% of 
records.[22] 
The Clinical Practice Research Datalink (formerly General Practice Research Database) is a 
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database of person-specific longitudinal records of consultations and diagnoses in primary care. 
Over 600 practices, covering 5–10% of the UK population, have been contributing data to CPRD 
since 1989.[23] Hospital Episode Statistics contains records of in-patient admissions in English 
NHS hospitals, including data on admission, diagnoses, treatment and discharge of each in-patient 
stay.[24] CPRD commissioned the linkage of their records externally, and Thames Cancer Registry 
and Northern and Yorkshire Cancer Registry and Information Service carried out the linkage of 
HES records to tumour registrations by matching on NHS number, sex, date of birth and 
postcode.[25-27] 
Methods 
Patient cohort 
We identified from the National Cancer Registry patients aged 0–24 years when diagnosed with a 
primary intracranial tumour between 1989 and 2006 as the cohort with primary care data, and 
between 1997 and 2006 as a second cohort with hospital data. We have included patients 
presenting up to age 24 years since they are often managed in specialist teenage cancer units. We 
defined intracranial tumours as those coded to a relevant location (supratentorial compartment, 
midline, cerebellum, brainstem, ventricular system, meninges, cranial nerves or other) in the ninth 
or tenth revision of the International Classification of Diseases (ICD),[28 29] with a compatible 
morphological code from the third edition of the International Classification of Childhood Cancer 
(diagnostic groups III, IX.b.2, IX.d.8 and X.a).[30] 
Tumour registrations were excluded with the same criteria as for National Statistics: records with 
invalid dates, unknown sex, unknown vital status, secondary or metastatic tumour, patients not 
resident in England and Wales, or records that failed ONS validity checks. Records of synchronous 
tumours (with an identical date of diagnosis relating to the same person) or multiple primary 
tumours (with same tumour location and person identifier) were also excluded.[31] Such records 
could have come from patients with a genetic predisposition such as neurofibromatosis or tuberous 
sclerosis and were likely to be under surveillance, and expected to have a diagnostic pathway 
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outside the scope of this study. 
We obtained the linked CPRD and HES records, and extracted a subset of consultations or in-
patient stays with one or more presenting features that fell into one of eight pre-specified groups of 
tumour-related symptoms and signs. 
Presenting features 
Symptoms, signs and diagnoses at each consultation are recorded as Read codes in CPRD [32] 
and as ICD-10 codes in HES. Each hospital “episode” may contain up to 14 “diagnoses” or 
presenting features, with the main feature recorded as the “primary diagnosis”. We searched the 
full code list to identify over 800 codes representing features that could be related to an intracranial 
tumour. These were grouped into eight categories: headache; other features of raised intracranial 
pressure (e.g. nausea, vomiting); convulsions; visual disturbance (e.g. features of cranial nerves II, 
III, IV or VI dysfunction); focal neurological deficit; growth or endocrine disorders; behavioural (e.g. 
cognitive) problems and general or non-specific symptoms (e.g. delayed milestone, irritability). We 
assumed a consultation or hospital stay to be tumour-related if the “primary diagnosis” in HES or 
any of the symptoms in CPRD came from one of the above groups. 
Each hospital episode can be further classified as “non-emergency” or “emergency” by its method 
of admission. In an emergency admission, patients were admitted via the Accident and Emergency 
department, directly by the general practitioner, via the bed bureau, urgently from an outpatient 
clinic or by urgent transfer from another hospital. 
The observation time in HES for each patient began on the later of the date of birth or the start of 
HES data and ended with the earlier of the date of death or the end of HES data. The observation 
time in CPRD began on the date of registration with the primary care practice, and ended with the 
earliest of the date of death, transfer-out date (if a patient had moved to a practice not included in 
CPRD) or last collection date (when data were last submitted). We divided the observation time for 
each individual into monthly intervals before and after the date of diagnosis in the National Cancer 
Registry, which is defined under international standards.[33 34] 
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The presentation rate is the number of hospital episodes (from HES) or primary care consultations 
(from CPRD) divided by the observation time, that is, the length of time during which an individual 
could present to primary care or hospitals and thus have a record in CPRD or HES. We reported 
presentation rates using the age at which patients presented, to mirror the normal developmental 
stages and clinical practice in paediatrics, for the following groups: 0–4, 5–11, 12–18 and 19–24 
years to examine the pattern in age-specific symptoms and signs before the diagnosis of an 
intracranial tumour. We also reported presentation rates for 0–1, 1–3, 3–6, 6–12 and over 12 
months from the date of definitive diagnosis to investigate the evolution of symptoms and signs 
before and after the diagnosis of an intracranial tumour. Rates and confidence intervals were 
estimated in generalised linear models with the number of presentations as the response, and the 
logarithm of the length of observation time as the offset. 
The presentation rates showed considerable month-to-month fluctuations. To demonstrate the 
underlying trend, we used generalised additive models with locally weighted regression (LOESS) 
to smooth monthly presentation rates in the time domain.[5 35] In a LOESS smoother, a low-
degree polynomial regression is fitted for each observation using observations that are close to the 
one of interest. This is repeated until the mean response of every observation has been estimated. 
A weighted least squares algorithm is used in the process, with the weight values determined by a 
tri-cube function: greater weights are assigned to observations nearer to the month at which the 
presentation rate was estimated.[35 36] The distribution of weights reflects the view that events 
close to the index presentation are more likely to be related, and are thus assigned greater 
weights, and events distant from the index presentation are less likely to be related, so carry less 
weight. 
Analyses were implemented using functions from the ‘gam’ package [37] and in the statistical 
language R.[38] Computationally intensive calculations were carried out on the High Performance 
Computing cluster at the London School of Hygiene and Tropical Medicine. 
Results 
We identified 9,799 patients diagnosed with an intracranial tumour between 1989 and 2006 from 
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the National Cancer Registry, after excluding 279 patients with ineligible records. Death-certificate-
only registrations, the information for the basis of registration came solely from the death 
certificate, comprised 0.6% of the records we analysed. 
We extracted 3,787 primary care records (CPRD) that were linked to 181 (1.85%) of these 9,799 
individuals. Because hospital records had only been linked to tumours registered from 1997, we 
extracted 60,351 HES records linked to 3,959 (78.2%) of the 5,061 individuals diagnosed since. 
Linkage of HES was proportionally more successful in patients aged 0–4 years, patients with a 
cerebellar or brainstem tumour, and patients with a tumour outside the sellar region (all P < 0.001) 
(Table 1). The number of patients with linked CPRD records is close to our expectation from its 
population coverage and the proportion of practices that consented to linkage (about half). The 
proportion of tumour records that were successfully linked varied by tumour morphology (P = 0.03), 
but not for sex (P = 0.4), age (P = 0.9), tumour location (P = 0.3) or behaviour (P = 0.2). 
The overall pattern 
Patients with an intracranial tumour presented with one or more tumour-related symptoms before 
diagnosis in 6,973 hospital admissions (of which 3,640 via an emergency route), at an overall 
presentation rate of 3.3 per 100 person-months (1.7 per 100 person-months for emergency 
admissions). The presentation rate increased from 1.3 per 100 person-months (95% CI: 1.1–1.4) in 
the period 6–12 months before diagnosis to 6.4 per 100 person-months (5.8–7.0) in the period 1–3 
months before diagnosis (Table 2). The steepest increase occurred in the final month before 
diagnosis, when the rate rose to 134.0 (130.4–137.6). Similarly, the emergency presentation rate 
increased from 0.6 per 100 person-months (95% CI: 0.5–0.7) to 73.0 (70.4–75.7) between 12 
months and the final month before diagnosis (Figure 1). The proportion of emergency 
presentations rose from 45% 6–12 months to 55% in the final month. 
Presentations in primary care were more frequent than in hospitals: 926 consultations for a tumour-
related symptom took place before diagnosis at an overall rate of 6.0 per 100 person-months. The 
frequency of consultations rose from 8.4 per 100 person-months (95% CI: 6.8–10.5) at 6–12 
months to 148.9 (131.9–168.1) in the final month (Table 2 and Figure 2). Patients were seen in 
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primary care over four times as often as in hospitals up to the final month before the tumour was 
diagnosed. The time at which the presentation rate began to rise steeply was also earlier in 
primary care (3–6 months before diagnosis) than in hospital (0–1 month). 
Presentation rates fell rapidly within the first three months after diagnosis, with a steeper fall 
occurring in primary care visits (Figure 1 and 2). The rate of emergency hospital visits, which were 
not subject to normal follow-up schedule, also fell rapidly after diagnosis. 
Primary care consultations 
Headache was the most common presenting symptom in patients older than 5 years with 
presentation rates increasing with age (0.64 per 100 person-months in 5–11 year-olds to 2.44 in 
19–24 year-olds), but was one of the uncommon symptoms in 0–4 year-olds (0.10; 95% CI: 0.04–
0.24). In this age group, other features of raised intracranial pressure (e.g. vomiting, increased 
head circumference) were far more common (0.42; 0.28–0.65) (Table 3A). 
Convulsions were unusual in patients under 18 years (between 0.20 and 0.30 per 100 person-
months) but were common in patients over 18 years (2.36; 1.64–3.40). Visual disturbance was the 
most common symptom group in 0–4 year-olds (0.49; 0.33–0.72), the second most common 
symptom group (0.35; 0.23–0.53) after headache in 5–11 year-olds and the third most common 
(0.48; 0.29–0.78) after headache and general non-specific symptoms in 12–18 year-olds. 
Patients began presenting to their general practitioners from about 24 months before the diagnosis 
of an intracranial tumour (see online supplementary material): mainly with headache or 
convulsions, and sometimes together with signs of cranial nerve II, III, IV or VI dysfunction or with 
growth or endocrine disorders (Table 3B). Consultation rates for focal neurological deficits, non-
specific features and behavioural problems began to rise 6–12 months before the diagnosis of an 
intracranial tumour. Features in every symptom group presented with increasing frequency, but 
those of raised intracranial pressure (e.g. nausea, vomiting, papilloedema, increased head 
circumference) were uncommon until the final month before diagnosis (rate = 10.3 per 100 person-
months, 95% CI: 6.47–16.3). Localising symptoms and signs such as visual disturbance and focal 
neurological deficits were far less prominent than non-specific symptoms. 
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Hospital presentations 
Although headache was unusual in 0–4 year-olds (0.07 per 100 person-months, 95% CI: 0.05–
0.10), it was one of the common symptoms in older patients (Table 4A). Other features of raised 
intracranial pressure (e.g. nausea, vomiting, papilloedema) were prominent in every age group 
(between 0.77 and 1.17 per 100 person-months), particularly in younger patients. Other common 
presentations included convulsions (between 0.28 and 0.61) and focal neurological deficits 
(between 0.20 and 0.33). 
Clinical features from every symptom group occurred with increasing frequency with time in every 
age group (Table 4B). Convulsions began to present from 12 months before an intracranial tumour 
was diagnosed (see online supplementary material). Features in other symptom groups were seen 
only from 3–6 months, with those of raised intracranial pressure seldom occurred until 1–3 months 
before diagnosis. 
Localising features such as focal neurological deficits and visual disturbance were not commonly 
detected before the brain tumour diagnosis: focal neurological deficits (0.54 per 100 person-
months, 95% CI: 0.40–0.73) were only one-third as frequent as raised intracranial pressure (1.45; 
1.20–1.74) or convulsions (1.46; 1.21–1.75) in the 1–3 months before diagnosis. Features of raised 
intracranial pressure (36.4 per 100 person-months, 95% CI: 34.6–38.4) were five times as common 
as focal neurological deficits (7.78; 6.96–8.71) or visual disturbance (6.49; 5.74–7.34) in the final 
month before diagnosis. 
A large proportion of admissions with headaches (82–96%) came through an emergency route 
(Table 4B). In contrast, a smaller proportion of presentations with other features of raised 
intracranial pressure (60–69%), convulsions (46–76%) or focal neurological features (52–74%) 
was admitted urgently. 
Discussion 
Every symptom presented with increasing frequency until the intracranial tumour was eventually 
diagnosed. The most common clinical features presented to hospitals were those of raised 
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intracranial pressure and convulsions. Headache and focal neurological deficits were not 
prominent, especially early in the natural history of intracranial tumours. This pattern was similar in 
all age groups, except among 0–4 year-olds, in whom headache was rarely reported. Other 
features of raised intracranial pressure (such as vomiting, increased head circumference) were 
detected more frequently in children under 4 years.[12] Our findings are consistent with earlier 
studies in which headache, vomiting and non-localising symptoms were generally found to be the 
more common features in the entire pre-diagnosis period,[9 10 13] but we have also examined 
when in the time course before the brain tumour diagnosis those symptoms were common. 
The primary care presentation rate for many symptoms and signs began to increase earlier than in 
hospital admissions, and with a more variable pattern: headache was, by far, the most common 
feature except in 0–4 year-olds, in whom features of raised intracranial pressure were more 
common. This is compatible with the development of language and cognitive functions in children 
and the capacity of the skull to accommodate an increase in intracranial pressure before the 
sutures fuse. Visual disturbances were among the more common and specific features and their 
presence, especially in 0–4 year-olds, should prompt consideration of an intracranial tumour as a 
possible cause. Very young or uncooperative children in whom an ophthalmic examination cannot 
be performed adequately should therefore be referred for specialist assessment.[8] 
Rising presentation rates in both primary and secondary care in the last few months before 
diagnosis of an intracranial tumour implies the diagnostic pathway in paediatric patients does not fit 
the model for adult patients, in which diagnostic delay is divided into discrete components of 
primary care and secondary care.[39-43] Healthcare professionals seeing children should therefore 
be aware of the pattern in the temporal development of clinical features that may require further 
investigations: in patients with repeat attendances with similar symptoms or a recent history of 
rapid symptom progression causing parental concern.[8] 
Other non-localising features (e.g. symptoms of raised intracranial pressure, general non-specific 
symptoms such as lethargy, fatigue, drowsiness, appetite loss, irritable, failure to thrive, etc.) were 
far more common than localising features, especially early in the natural history of intracranial 
tumours – a finding that is consistent with previous studies.[2 4 6 7 9 10 13 44] We also found that 
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changes in the proportion of emergency admissions before a diagnosis of an intracranial tumour 
were comparable with the pattern observed in adults.[45] 
Strengths and limitations 
Progression of brain tumour symptoms and signs has been extensively studied,[4 5 7 9-11 13-15 
46] culminating in the development of guidelines for clinical assessment.[8 47 48] Earlier studies 
have often been limited to examining this in a community-based or hospital-based cohort, usually 
in a single institution. Advances in record linkage methodology have enabled study of symptom 
progression and healthcare service use in a population-based cohort with a histologically verified 
diagnosis. Other advantages include greater accuracy of the data on tumour diagnosis and 
avoidance of recall and selection bias, a problem that affects data collected after diagnosis in 
patient interviews or manual review of medical notes. In using the date of diagnosis from the 
National Cancer Registry (derived under international standards[33 34]) to divide each patient’s 
history into pre-diagnosis and post-diagnosis periods, we have ensured consistency in the timing of 
emergence of clinical features when comparing results from primary care and hospital data. We 
have also been able to demonstrate (rather than to assume) a fall in the presentation rate, both in 
primary care and in hospitals, for every symptom group after the intracranial tumour diagnosis. 
This highlights the importance of a timely diagnosis in planning appropriate treatment. 
Although the primary care records were only available for a small number of patients, this is still 
one of the largest population-based cohort of children and young adults with a histologically 
verified brain tumour. Potential explanations for the lack of linked records include differences in 
geographical overlap with the National Cancer Registry, quality of matching variables, linkage 
algorithm efficiency, and each patient’s probability of healthcare service use. For example, patients 
with a tumour in the sellar region were more likely to have presented with endocrinopathies that 
were less likely to necessitate in-patient stays for their management. This would imply their 
medical history is less likely to be captured in HES. We do not have data on symptoms that 
occurred before the first clinical contact unless they were reported to general practitioners. Such 
data may only be obtained from interviewing patients or their parents, which would be susceptible 
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to bias from differential recall or participation. We are, however, confident that the data are 
representative of patients who presented to their general practitioners or admitted as in-patients in 
NHS hospitals, and the symptom data accurately reflect each clinician’s interpretation of the 
importance of presenting features. 
We have analysed the presentation rate, not simply the number of presentations, in order to avoid 
the bias associated with unequal observation time between patients. A fixed length of pre-
diagnosis interval has been used in some studies, but that may have introduced bias in estimation 
of the number of visits in patients with slow-growing tumours or of symptom interval in younger 
children. 
We have assumed homogeneity in the effect of tumour location and morphology when using 
generalised linear models to analyse presentation rates.[49-51] Variability associated with tumour 
location and morphology will be examined elsewhere. 
Conclusion and implications 
Among children and young adults with an intracranial tumour, non-localising features such as 
lethargy, drowsiness, failure to thrive, parental concern, headache and features of raised 
intracranial pressure were far more common than specific features such as focal neurological 
deficits throughout the pre-diagnosis period. In all age groups, cranial nerve II, III, IV or VI 
dysfunction was also common in primary care. Many of these symptoms occurred with increasing 
frequency with tumour progression. Features of raised intracranial pressure become the most 
common group of presenting features in the final month before diagnosis. 
The pattern of symptom development was complex, so the predictive power of an isolated feature 
or combination of features is likely to be weak. The possibility of an intracranial tumour as a 
differential diagnosis should be considered in patients presenting with symptoms that fail to settle 
or progress rapidly, rather than relying on the presence or absence of specific symptoms or signs.  
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What is already known on this topic 
1. The clinical features of intracranial tumours are diverse and often non-specific. 
2. Suspicion of an intracranial tumour is often only triggered when a child presented with 
localising features such as focal neurological deficits. 
3. The time to diagnosis for intracranial tumours was longer than for many other childhood 
cancers. The predictive power of symptoms and signs is poor. 
What this study adds 
1. In primary care, the main features were those of visual disturbance in children aged 0–4 
years, and headache in older children and young adults. 
2. Features of raised intracranial pressure were the most common group of symptoms 
presented in hospitals. They emerged 3–6 months before diagnosis. 
3. The proportion of emergency presentations to hospitals rose steadily from 35% over 12 
months before diagnosis to 55% by the time of diagnosis. 
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Figures 
Figure 1 
Pattern of hospital presentations in children and young adults with an intracranial tumour before 
and after diagnosis (time = 0 at brain tumour diagnosis): England, 1997-2006. 
Black line: change in frequency of all hospital presentations (black dots) after locally weighted 
regression (LOESS) smoothing. Red line: change in frequency of emergency presentations (red 
dots) after LOESS smoothing. 
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Figure 2 
Pattern of primary care presentations in children and young adults with an intracranial tumour 
before and after diagnosis (time = 0 at brain tumour diagnosis): England, 1989-2006. 
Solid line: change in frequency of primary care presentations (grey dots) after locally weighted 
regression smoothing. 
 
Table 1: Distribution of demographical characteristics in patients from the National Cancer
Registry with and without linked HES or CPRD records.
Linked to HES (1997–2006) Linked to CPRD (1989–2006)
Yes No Yes No
Count % Count % Count % Count %
Total 3,959 1,102 181 9,618
Sex
Female 1,766 44.6 499 45.3 79 43.6 4,454 46.3
Male 2,193 55.4 603 54.7 102 56.4 5,164 53.7
Age at diagnosis
0–4 years 954 24.1 174 15.8 36 19.9 2,079 21.6
5–11 years 1,180 29.8 299 27.1 54 29.8 2,737 28.5
12–18 years 948 23.9 322 29.2 44 24.3 2,325 24.2
19–24 years 877 22.2 307 27.9 47 26.0 2,477 25.8
Tumour location
Supratentorial 1,011 25.5 258 23.4 50 27.6 2,134 22.2
Midline 410 10.4 246 22.3 29 16.0 1,365 14.2
Cerebellum 586 14.8 71 6.4 25 13.8 1,255 13.0
Brainstem 360 9.1 53 4.8 16 8.8 718 7.5
Ventricles 94 2.4 11 1.0 2 1.1 244 2.5
Meninges 103 2.6 26 2.4 5 2.8 271 2.8
Cranial nerves 134 3.4 37 3.4 7 3.9 401 4.2
Other 1,261 31.9 400 36.3 47 26.0 3,230 33.6
Tumour morphology
Astrocytoma
pilocytic 689 17.4 107 9.7 24 13.3 1,160 12.1
all other subtypes 931 23.5 167 15.2 40 22.1 2,171 22.6
Embryonal tumour 630 15.9 50 4.5 22 12.2 1,210 12.6
Glioma 477 12.0 105 9.5 17 9.4 1,156 12.0
Choroid plexus tumour 299 7.6 48 4.4 9 5.0 632 6.6
Sellar region tumour 230 5.8 179 16.2 18 9.9 849 8.8
Germ cell tumour 145 3.7 37 3.4 5 2.8 327 3.4
Nerve sheath tumour 136 3.4 39 3.5 7 3.9 299 3.1
Meningioma 103 2.6 21 1.9 7 3.9 262 2.7
Pineal gland tumour 43 1.1 13 1.2 7 3.9 92 1.0
Haemangioma 19 0.5 37 3.4 0 0.0 108 1.1
Other specified tumour 94 2.4 108 9.8 10 5.5 264 2.7
Unspecified neoplasm 163 4.1 191 17.3 15 8.3 1,088 11.3
Tumour behaviour
Benign 572 14.4 129 11.7 26 14.4 1,376 14.3
Borderline 838 21.2 583 52.9 56 30.9 2,397 24.9
Malignant 2,549 64.4 390 35.4 99 54.7 5,845 60.8
CPRD = Clinical Practice Research Datalink, HES = Hospital Episode Statistics.
Table 2: Presentation rate (per 100 person-months) from HES (1997–2006) and CPRD-linked tumour registrations (1989–2006) in patients aged 0–24 years diagnosed with
an intracranial tumour in England.
Hospital presentations Primary care presentations
All admissions Emergency only
Time from diagnosis
(months)
Observation time
(person-months) Count Rate 95% CI Count Rate 95% CI %*
Observation time
(person-months) Count Rate 95% CI
Before diagnosis
12+ months 164,643.2 635 0.4 0.4 – 0.4 224 0.1 0.1 – 0.2 35.3 13,560.7 417 3.1 2.8 – 3.4
6–12 21,787.0 276 1.3 1.1 – 1.4 125 0.6 0.5 – 0.7 45.3 972.1 82 8.4 6.8 – 10.5
3–6 11,466.0 281 2.5 2.2 – 2.8 151 1.3 1.1 – 1.5 53.7 497.2 75 15.1 12.0 – 18.9
1–3 (a) 7,812.3 498 6.4 5.8 – 7.0 260 3.3 2.9 – 3.8 52.2 340.8 91 26.7 21.7 – 32.8
0–1 month (b) 3,943.6 5,283 134.0 130.4 – 137.6 2,880 73.0 70.4 – 75.7 54.5 175.3 261 148.9 131.9 – 168.1
After diagnosis
0–1 month 3,864.6 3,897 100.8 97.7 – 104.1 1,067 27.6 26.0 – 29.3 27.4 175.0 200 114.3 99.5 – 131.3
1–3 7,569.9 8,209 108.4 106.1 – 110.8 1,344 17.8 16.8 – 18.7 16.4 334.3 159 47.6 40.7 – 55.6
3–6 11,074.1 8,002 72.3 70.7 – 73.9 1,360 12.3 11.6 – 13.0 17.0 482.3 196 40.6 35.3 – 46.7
6–12 20,871.8 11,405 54.6 53.6 – 55.7 1,859 8.9 8.5 – 9.3 16.3 910.9 245 26.9 23.7 – 30.5
12+ months 161,455.1 21,858 13.5 13.4 – 13.7 3,949 2.4 2.4 – 2.5 18.1 11,643.2 2,062 17.7 17.0 – 18.5
(a) This interval lasts from 3 months before diagnosis to the day before 1 month before diagnosis.
(b) This interval lasts from 1 month before diagnosis to the date of diagnosis (inclusive).
* Proportion of hospital episodes that were admitted via an emergency route.
CPRD = Clinical Practice Research Datalink, HES = Hospital Episode Statistics.
Table 3: Primary care presentation rate (per 100 person-months) for each symptom group from CPRD-linked tumour registrations before intracranial tumour
diagnosis in patients aged 0–24 years, England, 1989–2006.
A. By age at presentation:
Age at presentation 0–4 years 5–11 years 12–18 years 19–24 years
Length of observation
(person-months)
4,945.8 6,062.1 3,342.0 1,228.5
Symptom group Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI
Headache 5 0.10 0.04 – 0.24 39 0.64 0.47 – 0.88 53 1.59 1.21 – 2.08 30 2.44 1.71 – 3.49
Raised ICP 21 0.42 0.28 – 0.65 11 0.18 0.10 – 0.33 9 0.27 0.14 – 0.52 6 0.49 0.22 – 1.09
Convulsions 10 0.20 0.11 – 0.38 17 0.28 0.17 – 0.45 10 0.30 0.16 – 0.56 29 2.36 1.64 – 3.40
Visual disturbance 24 0.49 0.33 – 0.72 21 0.35 0.23 – 0.53 16 0.48 0.29 – 0.78 8 0.65 0.33 – 1.30
Focal deficits 14 0.28 0.17 – 0.48 13 0.21 0.12 – 0.37 11 0.33 0.18 – 0.59 7 0.57 0.27 – 1.20
Growth or endocrine 5 0.10 0.04 – 0.24 10 0.16 0.09 – 0.31 10 0.30 0.16 – 0.56 8 0.65 0.33 – 1.30
Behavioural 21 0.42 0.28 – 0.65 19 0.31 0.20 – 0.49 3 0.09 0.03 – 0.28 0 0.00 not estimated
General 19 0.38 0.25 – 0.60 22 0.36 0.24 – 0.55 22 0.66 0.43 – 1.00 20 1.63 1.05 – 2.52
B. By time from diagnosis:
Time from diagnosis 6–12 months before 3–6 months before 1–3 months before 0–1 months before
Symptom group Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI Count Rate 95% CI
Headache 16 1.65 1.01 – 2.69 9 1.81 0.94 – 3.48 22 6.46 4.25 – 9.81 49 27.96 21.13 – 36.99
Raised ICP 1 0.10 0.01 – 0.73 3 0.60 0.19 – 1.87 3 0.88 0.28 – 2.73 18 10.27 6.47 – 16.30
Convulsions 6 0.62 0.28 – 1.37 19 3.82 2.44 – 5.99 10 2.93 1.58 – 5.45 7 3.99 1.90 – 8.38
Visual disturbance 9 0.93 0.48 – 1.78 9 1.81 0.94 – 3.48 8 2.35 1.17 – 4.69 15 8.56 5.16 – 14.20
Focal deficits 5 0.51 0.21 – 1.24 2 0.40 0.10 – 1.61 6 1.76 0.79 – 3.92 14 7.99 4.73 – 13.49
Growth or endocrine 7 0.72 0.34 – 1.51 3 0.60 0.19 – 1.87 2 0.59 0.15 – 2.35 4 2.28 0.86 – 6.08
Behavioural 4 0.41 0.15 – 1.10 4 0.80 0.30 – 2.14 1 0.29 0.04 – 2.08 5 2.85 1.19 – 6.85
General 5 0.51 0.21 – 1.24 8 1.61 0.80 – 3.22 9 2.64 1.37 – 5.08 24 13.69 9.18 – 20.43
CPRD = Clinical Practice Research Datalink, ICP = intracranial pressure.
Table 4: Hospital presentation rate (per 100 person-months) for each symptom group from HES-linked tumour registrations before intracranial tumour diagnosis in patients aged
0–24 years, England, 1997–2006.
A. By age at presentation:
Age at presentation 0–4 years 5–11 years 12–18 years 19–24 years
Length of observation
(person-months)
55,655.9 70,115.3 58,313.0 26,435.0
Symptom group Count Rate 95% CI % Count Rate 95% CI % Count Rate 95% CI % Count Rate 95% CI %
Headache 41 0.07 0.05 – 0.10 83 220 0.31 0.27 – 0.36 90 178 0.31 0.26 – 0.35 87 79 0.30 0.24 – 0.37 86
Raised ICP 650 1.17 1.08 – 1.26 62 710 1.01 0.94 – 1.09 67 449 0.77 0.70 – 0.84 64 203 0.77 0.67 – 0.88 66
Convulsions 244 0.44 0.39 – 0.50 64 198 0.28 0.25 – 0.32 53 333 0.57 0.51 – 0.64 52 162 0.61 0.53 – 0.71 59
Visual disturbance 103 0.19 0.15 – 0.22 37 148 0.21 0.18 – 0.25 57 126 0.22 0.18 – 0.26 65 54 0.20 0.16 – 0.27 54
Focal deficits 186 0.33 0.29 – 0.39 54 145 0.21 0.18 – 0.24 66 135 0.23 0.20 – 0.27 47 54 0.20 0.16 – 0.27 59
Growth or endocrine 31 0.06 0.04 – 0.08 39 164 0.23 0.20 – 0.27 19 75 0.13 0.10 – 0.16 25 75 0.28 0.23 – 0.36 25
Behavioural 26 0.05 0.03 – 0.07 31 35 0.05 0.04 – 0.07 51 29 0.05 0.03 – 0.07 62 11 0.04 0.02 – 0.08 73
General 131 0.24 0.20 – 0.28 60 66 0.09 0.07 – 0.12 59 45 0.08 0.06 – 0.10 58 14 0.05 0.03 – 0.09 86
B. By time from diagnosis:
Time from diagnosis 6–12 months before 3–6 months before 1–3 months before 0–1 months before
Symptom group Count Rate 95% CI % Count Rate 95% CI % Count Rate 95% CI % Count Rate 95% CI %
Headache 27 0.12 0.08 – 0.18 96 28 0.24 0.17 – 0.35 89 51 0.65 0.50 – 0.86 82 338 8.57 7.70 – 9.53 91
Raised ICP 35 0.16 0.12 – 0.22 69 40 0.35 0.26 – 0.48 60 113 1.45 1.20 – 1.74 63 1,437 36.44 34.60 – 38.37 68
Convulsions 101 0.46 0.38 – 0.56 66 105 0.92 0.76 – 1.11 70 114 1.46 1.21 – 1.75 76 402 10.19 9.24 – 11.24 46
Visual disturbance 13 0.06 0.03 – 0.10 54 12 0.10 0.06 – 0.18 25 33 0.42 0.30 – 0.59 45 256 6.49 5.74 – 7.34 66
Focal deficits 17 0.08 0.05 – 0.13 65 27 0.24 0.16 – 0.34 74 42 0.54 0.40 – 0.73 52 307 7.78 6.96 – 8.71 63
Growth or endocrine 12 0.06 0.03 – 0.10 8 27 0.24 0.16 – 0.34 22 37 0.47 0.34 – 0.65 27 154 3.91 3.33 – 4.57 30
Behavioural 6 0.03 0.01 – 0.06 17 9 0.08 0.04 – 0.15 56 6 0.08 0.03 – 0.17 67 50 1.27 0.96 – 1.67 58
General 11 0.05 0.03 – 0.09 64 18 0.16 0.10 – 0.25 67 25 0.32 0.22 – 0.47 48 134 3.40 2.87 – 4.02 74
Percentages refer to the proportion of hospital episodes that were admitted via an emergency route.
HES = Hospital Episode Statistics, ICP = intracranial pressure.
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● Graphs on the top row illustrate changes in primary care presentations. Those on the 
bottom row illustrate changes in hospital presentations. 
● Primary care presentations: 
○ grey dotted line = observed rates 
○ black solid line = predicted rates after LOESS smoothing 
● Hospital presentations: 
○ grey line = observed rates of all admissions 
○ black line = observed rates of emergency admissions only 
○ blue line = predicted rates of all admissions after LOESS smoothing 
○ red lines = predicted rates of emergency admissions after LOESS smoothing 
● A common scale was used for the x­axes, but we did not use an identical scale for the 
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● The frequency of primary care consultations for headache began to increase 24 
months before the diagnosis of an intracranial tumour. The frequency of hospital 
admissions for headache did not increase until six months before diagnosis. The red 
and blue lines are very close because a high proportion of hospital episodes was 
admitted as an emergency. 
● The frequency of presentations with features of raised intracranial pressure (other 
than headache) did not begin to increase until about six months before brain tumour 
diagnosis in both primary and secondary care, implying that the tumour was growing 
undetected and could be giving rise to complications in the last six months. 
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● Convulsions and visual disturbance were not common in primary care. Fluctuations in their 
consultation rates were large (grey line) due to very few consultations for those features being 
recorded. Their underlying trends were only made obvious after smoothing (black line). 
● The frequency of primary care consultations for convulsions or visual disturbance began to 
increase 12 months before brain tumour diagnosis (black line), at a point earlier than when the 
frequency of hospital admissions with those symptoms began to increase. 
● The difference between the pattern of primary and secondary care visits for visual disturbance 
was more pronounced. Dysfunction of cranial nerve II, III, IV or VI was seen in primary care with 
increasing frequency 24 months before a brain tumour diagnosis, long before those patients 
began to present in hospitals 3–6 months before the definitive diagnosis of tumour. 
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● Focal neurological deficits were uncommon in both primary and secondary care, until 
the last 3–6 months before the diagnosis of an intracranial tumour. 
● Changes in the frequency of consultations for growth or endocrine disorders occurred 
much earlier in primary care (about 24 months before the intracranial tumour was 
diagnosed) than in hospitals (around six months before diagnosis). 
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Secondary care: 
 
● Consultations in primary care for general or non­specific symptoms such as lethargy, 
appetite loss gradually increased in frequency 6–12 months before the brain tumour 
diagnosis. The rise in frequency became steeper from that time, with a corresponding 
increase in hospital admissions with those symptoms. 
● Behavioural problems were uncommon. The increase in presentations was likely to 
be driven by an increase in the frequency at which other symptoms and signs 
occurred. 
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